In one study, the combination of piperlongumine and docetaxel showed strong anticancer activity due to the suppression of various proliferative and apoptotic molecular markers associated with breast cancer, and the negative regulation of Bcl-2 and survivin. This evidence concerns the gene BCL2 and breast carcinoma.